Literature DB >> 16117196

Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

A S Alzahrani1, G Mohamed, A Al Shammary, S Aldasouqi, S Abdal Salam, M Shoukri.   

Abstract

UNLABELLED: Following the initial management, some patients with differentiated thyroid cancer (DTC) develop a state of high thyroglobulin (Tg) and negative diagnostic radioactive iodine (RAI) whole body scan (DxWBS). The predisposing factors and outcome of this condition are unclear. In this study, our objectives were to determine the predictive factors for the development of high Tg and negative DxWBS (Tg+/scan-) and to study the long-term course of the disease in patients with this condition.
METHODS: We, retrospectively, reviewed the medical records of a cohort of 105 non-selected DTC patients (26 males and 79 females; median age 37.7 yr, range 7-72). None of these patients had positive Tg antibodies or distant metastases. All Tg levels were obtained off thyroid hormone therapy. At the first follow-up visit after RAI ablation (13 +/- 7.6 months), patients were classified into those with low Tg (<2 ng/ml off L-T4) and negative DxWBS (control group) and those with high Tg ( > or = 22 ng/ ml off L-T4) and negative DxWBS (Tg+/scan- group). Using univariate and multivariate logistic regression analyses, we evaluated a number of parameters (see results) for their association with the development of Tg+/scan-. In addition, the long-term course of the disease in Tg+/scan- group was analyzed.
RESULTS: In univariate analysis, the following factors were found to be significantly associated with Tg+/scan-: perithyroidal tumor extension (p=0.025), soft tissue invasion (p=0.001), cervical lymph node metastases (p=0.014) and Tg level before RAI ablation (p=0.015). In multivariate analysis, only soft tissue invasion remained significantly associated with Tg+/scan- [p 0.001, odds ratio, 15.6 (95% Cl, 2.96-82.06)]. Age, sex, duration of goiter before surgery, pressure symptoms, tumor size, tumor multifocality, lymph nodedissection at initial surgery, tumor-node-metastasis (TNM) stage, and RAI ablative dose were not associated with Tg+/ scan-. In 53 patients with Tg+/scan-, 42 cases were followed without any therapeutic intervention; over a median follow-up of 71.6 months (range, 13-144.7), 31 cases had a spontaneous remission and 11 cases continued to have a persistent disease (Tg > or = 2 ng/ml, negative DxWBS, and no palpable disease or distant metastases); Tg declined from 9.32 +/- 9.91 ng/ml at first visit after RAI ablation to 1.59 +/- 5.39 ng/ml at last visit (p<0.0001). In the other 11 cases of Tg+/scan- group, one or more therapeutic interventions (RAI, surgery, or external radiotherapy) were undertaken. Over a median follow-up of 98.4 months (range, 6-147), Tg decreased from 110.2 +/- 147.5 to 23.5 +/- 41.2 ng/ml (p 0.026); 4 cases achieved remission, 5 cases continued to have persistent disease, and 2 cases had progression of their disease, which led to their death.
CONCLUSION: Soft tissue invasion on original surgery strongly predicts the development of Tg+/scan- in DTC patients. The long-term course of the disease is mostly favorable especially when the Tg level is only modestly elevated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16117196     DOI: 10.1007/BF03347243

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  Intraoperative ultrasonography improves identification of recurrent thyroid cancer.

Authors:  John K Karwowski; R Brooke Jeffrey; I Ross McDougall; Ronald J Weigel
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

2.  131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?

Authors:  I R McDougall
Journal:  Thyroid       Date:  1997-08       Impact factor: 6.568

Review 3.  Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.

Authors:  V Fatourechi; I D Hay
Journal:  Semin Nucl Med       Date:  2000-04       Impact factor: 4.446

4.  Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.

Authors:  F Pacini; L Agate; R Elisei; M Capezzone; C Ceccarelli; F Lippi; E Molinaro; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

5.  Urinary iodine excretion and maternal thyroid function. During pregnancy and postpartum.

Authors:  Mohammed Salleh M Ardawi; Hassan A Nasrat; Bader E Mustafa
Journal:  Saudi Med J       Date:  2002-04       Impact factor: 1.484

6.  Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.

Authors:  Vahab Fatourechi; Ian D Hay; Houman Javedan; Gregory A Wiseman; Brian P Mullan; Colum A Gorman
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

7.  Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.

Authors:  A S Alzahrani; H Raef; A Sultan; S Al Sobhi; S Ingemansson; M Ahmed; A Al Mahfouz
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

8.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

9.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

10.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.

Authors:  M W Ashcraft; A J Van Herle
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

View more
  9 in total

1.  Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up.

Authors:  Giuseppe Barbesino; Melanie Goldfarb; Sareh Parangi; Jingyun Yang; Douglas S Ross; Gilbert H Daniels
Journal:  Thyroid       Date:  2012-03-02       Impact factor: 6.568

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Applicability of Adults 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines for Postoperative Risk Stratification and Postradioiodine Treatment Dynamic Risk Stratification in Pediatric Population.

Authors:  Shashank Shekhar Singh; Bhagwant Rai Mittal; Ashwani Sood; Anish Bhattacharya; Ganesh Kumar; Amit Singh Shekhawat; Harpreet Singh
Journal:  World J Nucl Med       Date:  2022-07-19

4.  Biochemical persistence in thyroid cancer: is there anything to worry about?

Authors:  Fabián Pitoia; Pitoia Fabián; Erika Abelleira; Abelleira Erika; Hernán Tala; Tala Hernán; Fernanda Bueno; Bueno Fernanda; Carolina Urciuoli; Urciuoli Carolina; Graciela Cross; Cross Graciela
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

5.  Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members.

Authors:  Robert C Smallridge; Nancy Diehl; Victor Bernet
Journal:  Thyroid       Date:  2014-09-05       Impact factor: 6.568

Review 6.  Persistent Elevation of Thyroglobulin in Patient Treated for Differentiated Thyroid Cancer: A Ten-Year Review.

Authors:  Sarah Khan; Roopashree Prabhushankar; Emily Leary; Uzma Z Khan
Journal:  Mo Med       Date:  2017 Sep-Oct

7.  BEHAVIOUR OF EARLY THYROGLOBULIN AFTER TOTAL THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER.

Authors:  D Pérez; M Marulanda; A Sanabria
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Jul-Sep       Impact factor: 0.877

8.  Value of the Postablative Thyroglobulin Measurements for Assessment of Disease-Free Status in Patients with Differentiated Thyroid Cancer.

Authors:  Nahla Dessoki; Ibrahim Nasr; Ahmed Badawy; Ismail Ali
Journal:  Indian J Nucl Med       Date:  2019 Apr-Jun

9.  Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?

Authors:  Hilda Wong; Kai P Wong; Thomas Yau; Vikki Tang; Roland Leung; Joanne Chiu; Brian Hung-Hin Lang
Journal:  Ann Surg Oncol       Date:  2012-05-11       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.